Rosetta Genomics Ltd. (NASDAQ:ROSG) rose in morning trading after the provider of microRNA-based and other molecular diagnostics was granted a U.S. patent allowance for the use of gene expression signature for the classification of kidney tumors.
Shares advanced 12% to $0.950 at 11:40 a.m. in New York.
The U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to “Gene Expression Signature for Classification of Kidney Tumors,” the Rehovot, Israel-based company said in a statement on Monday.
The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).
This U.S. patent allowance complements the intellectual property protection for Rosetta’s kidney cancer test, which is covered in a U.S. patent granted in July of 2015.
The patent is owned jointly with Tel Hashomer Medical Research Ltd., the technology transfer company of the Chaim Sheba Medical Center in Israel.
“This patent allowance expands our leading intellectual property position in microRNA technology, and further protects our mi-KIDNEY sub-classification assay,” CEO Kenneth Berlin said in the statement.
Kidney cancer is among the 10 most common cancers in both men and women with approximately 61,000 new cases of primary kidney tumors and 14,000 deaths per year in the U.S.